Micromedic Technologies Ltd. (TASE:MCTC) portfolio company Micro Rap Ltd. today reported that it successfully completed a trial to test the effectiveness of its diagnostic kit for type-1 diabetes (juvenile diabetes and latent autoimmune diabetes in adults (LADA)), based on RadioImmunoAssay technologies.
The trial, conducted at the Medical School of the Technion Israel Institute of Technology, included 60 samples. The diagnostic kit was able to identify 83.3% of the patients, though it identified the antibody in 13.3% of the control group of healthy persons.
On the basis of the results, Micro Rap will apply for marketing permits for the diagnostic kit, first in Europe, and then in the US. The company believes that it will complete the application for European marketing in the second half of the year.
Micro Rap is simultaneously pursuing the development of a diagnostic kit based on Elisa technology.
Micromedic purchased the commercial rights to the diabetes biomarker from BioRap Technologies Ltd., the technology transfer arm of the Bruce and Ruth Rappaport Institute of Medical Sciences at the Technion Faculty of Medicine. Micromedic owns 85% of Micro Rap, and BioRap owns 15%.
Published by Globes [online], Israel business news - www.globes-online.com - on January 28, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009